Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

NCT00751621 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immunodeficiency (PID)

Interventions

BIOLOGICAL: IgPro20

Sponsor

CSL Behring